<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;The management of vulval skin disorders.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Royal College of Obstetricians and Gynaecologists (RCOG). The management of vulval skin disorders. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2011 Feb. 23 p.&amp;nbsp;(Green-top guideline; no. 58).&amp;nbsp; [83 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Autoimmune disease, not elsewhere classified  (279.49); Candidiasis of unspecified site  (112.9); Candidiasis of vulva and vagina  (112.1); Circumscribed scleroderma  (701.0); Lichen planus  (697.0); Unspecified disorder of thyroid  (246.9); Venereal disease, unspecified  (099.9); Vulvar intraepithelial neoplasia II [VIN II]  (624.02)"/><FieldValue Value="MSH: Aminoquinolines ; Anti-Inflammatory Agents, Non-Steroidal ; Autoimmune Diseases ; Biopsy ; Calcineurin Inhibitors ; Candidiasis ; Candidiasis, Vulvovaginal ; Clobetasol ; Cytosine ; Dermatologic Agents ; Diabetes Mellitus ; Education, Medical, Graduate ; Emollients ; Gynecologic Surgical Procedures ; Gynecology ; Laser Therapy ; Lichen Planus ; Medical History Taking ; Reconstructive Surgical Procedures ; Referral and Consultation ; Scleroderma, Localized ; Self-Examination ; Sexual Dysfunction, Physiological ; Sexually Transmitted Diseases ; Skin Diseases ; Skin Tests ; Steroids ; Tacrolimus ; Thyroid Diseases ; Vulvar Diseases ; Vulvar Lichen Sclerosus ; Vulvar Neoplasms "/><FieldValue Value="MTH: Aminoquinolines ; Anti-Inflammatory Agents, Non-Steroidal ; Autoimmune disease NEC in ICD9CM ; Biopsy ; Biopsy of skin procedure ; Calcineurin inhibitor ; Candidiasis ; Candidiasis, Vulvovaginal ; Cidofovir ; Dermatologic disorders ; Diabetes Mellitus ; Emollients ; follow-up ; Gynecology ; Hypersensitivity skin testing ; Laser Therapy ; Lichen Planus ; Localized scleroderma ; Physiological Sexual Disorders ; Pimecrolimus ; Reconstructive Surgical Procedures ; Serum ferritin measurement ; Sexually Transmitted Diseases ; Steroids ; Tacrolimus ; Thyroid Diseases ; Vulval intraepithelial neoplasia "/><FieldValue Value="PDQ: biopsies ; cidofovir ; imiquimod ; laser surgery ; laser therapy ; tacrolimus "/><FieldValue Value="SNOMEDCT_US: Application of cream to skin  (225131002); Autoimmune disease  (85828009); Biopsy  (129314006); Biopsy  (86273004); Biopsy of skin  (240977001); Calcineurin inhibitor  (416587008); Calcineurin inhibitor  (416798007); Candidal vulvovaginitis  (72605008); Candidiasis  (78048006); Candidiasis of vulva  (1085006); Cidofovir  (108688007); Cidofovir  (386894007); Clobetasol  (419129004); Clobetasol  (48614001); Clobetasol propionate  (32197004); Cytosine  (72069001); Diabetes mellitus  (73211009); Disorder of skin  (95320005); Disorder of thyroid gland  (14304000); Disorder of vulva  (5089007); Emollient  (373380003); Emollient  (48279009); Gynecology  (394586005); Hypersensitivity skin testing  (164838003); Hypersensitivity skin testing  (268377001); Hypersensitivity skin testing  (53309004); Imiquimod  (108939005); Imiquimod  (386941002); Laser surgery  (35631009); Lichen planus  (4776004); Lichen planus of vulva  (237112004); Lichen sclerosus et atrophicus of the vulva  (198380007); Lichen sclerosus et atrophicus of the vulva  (26348009); Lichen simplex of vulva  (402243008); Localized scleroderma  (201048007); Neoplasm of vulva  (126922007); Non-steroidal anti-inflammatory agent  (16403005); Non-steroidal anti-inflammatory agent  (372665008); Operation on female genital organs  (12658000); Pimecrolimus  (385580005); Pimecrolimus  (385581009); Reconstruction procedure  (122465003); Reconstruction procedure  (129377008); Self-examination  (409978001); Serum ferritin measurement  (269821003); Sexually transmitted infectious disease  (8098009); Skin agent  (373516000); Skin agent  (65628000); Steroid  (116566001); Tacrolimus  (109129008); Tacrolimus  (386975001); Vulval intraepithelial neoplasia (VIN)  (399382009); Vulval intraepithelial neoplasia (VIN)  (399933001); Vulval intraepithelial neoplasia grade 2  (276874005)"/><FieldValue Value="UMD: Lasers, Carbon Dioxide, Surgical/Dermatologic  (16-942)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Vulval skin disorders, including dermatitis, lichen simplex, vulval candidiasis, lichen sclerosus, lichen planus, and vulvar intraepithelial neoplasia (VIN)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Allergy and Immunology" /><FieldValue Value="Dermatology" /><FieldValue Value="Family Practice" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Oncology" /><FieldValue Value="Plastic Surgery" /><FieldValue Value="Surgery" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To review the diagnosis and management of common vulval dermatoses seen in general gynaecological practice and the role of specialist training and support&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adult women with symptoms and/or signs of vulval skin disorders&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis/Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patient history (personal, medical, drug, family) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of signs and symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Testing for thyroid disease, diabetes, and sexually transmitted infections if clinically indicated &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Skin biopsy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Investigation for other autoimmune diseases in women with lichen planus or lichen sclerosus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Serum ferritin levels &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Skin patch testing &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment/Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Topical ultrapotent steroids (e.g., clobetasol propionate) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Topical calcineurin inhibitors (tacrolimus, pimicrolimus) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgery and carbon dioxide laser vaporisation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Local surgical excision for vulvar intraepithelial neoplasia (VIN) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reconstructive surgery &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-surgical alternative treatment (topical imiquimod cream, cidofovir, laser therapy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Avoidance of irritants &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of emollients and advice on care of vulval skin &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Long-term surveillance and follow-up &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Advice and referral on sexual problems &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Encouragement of patients on self-examination &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Training of general gynaecologists in the management of vulval disorders &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Specialist referral &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Incidence of vulval skin disorders &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Resolution of symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Response rate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Relapse rate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of squamous cell cancer &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Accuracy and specificity of diagnosis &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Cochrane Library and the Cochrane Register of controlled trials were searched for relevant randomised controlled trials, systematic reviews and meta-analyses. A search of Medline from 1980 to January 2010 was also carried out. The database was searched using the MeSH terms 'pruritus vulvae', 'lichen simplex', 'lichen sclerosus', 'lichen planus', 'vulva and dermatosis', 'vulva and candidiasis', 'vulva and disease and diagnosis' and 'vulvar intraepithelial neoplasia', including all subheadings. This search was combined with a keyword search using the terms 'disease and diagnosis' and limited to 'English language and women and humans'. Databases searched were the Cochrane Database of Systematic Reviews, DARE, EMBASE, Medline, PubMed, the National Library of Health and the National Guideline Clearinghouse. Other related guidelines were available from the British Association of Sexual Health and HIV, the National Institute for Health and Clinical Excellence, the Association of Physicians in Obstetrics and Gynecology and the British Association of Dermatologists.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The definition of the type of review used in this guideline was adult women referred to secondary care with symptoms and/or signs of vulval skin disorders, and the interventions to be studied were specified as the role of history taking, examination and investigations in the diagnosis and management of vulval skin disorders, the use of ultrapotent steroids and alternatives in vulval dermatoses and the provision of surveillance in secondary care for women with vulval disorders.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The research questions were developed and submitted for peer review.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Classification of Evidence Levels&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1++&lt;/strong&gt; High-quality meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a very low risk of bias&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1+&lt;/strong&gt; Well-conducted meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a low risk of bias&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1&amp;ndash;&lt;/strong&gt; Meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a high risk of bias&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2++&lt;/strong&gt; High-quality systematic reviews of case&amp;ndash;control or cohort studies or high-quality case&amp;ndash;control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2+&lt;/strong&gt; Well-conducted case&amp;ndash;control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2&amp;ndash;&lt;/strong&gt; Case&amp;ndash;control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;3&lt;/strong&gt; Non-analytical studies, e.g., case reports, case series&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;4&lt;/strong&gt; Expert opinion&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Two independent reviewers assessed the literature generated by the review to identify recommendations and the supporting evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Reviewing and Grading of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Once the evidence has been collated for each clinical question it needs to be appraised and reviewed (refer to section 3 in &quot;Development of RCOG Green-top guidelines: producing a clinical practice guideline&quot; for information on the formulation of the clinical questions; see the &quot;Availability of Companion Documents&quot; field). For each question, the study type with least chance of bias should be used. If available, randomised controlled trials (RCTs) of suitable size and quality should be used in preference to observational data. This may vary depending on the outcome being examined.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The level of evidence and the grade of the recommendations used in this guideline originate from the guidance by the Scottish Intercollegiate Guidelines Network (SIGN) Grading Review Group, which incorporates formal assessment of the methodological quality, quantity, consistency, and applicability of the evidence base. The methods used to appraise individual study types are available from the SIGN Web site (&lt;a href=&quot;http://www.sign.ac.uk/methodology/checklists.html&quot; title=&quot;SIGN Web site&quot;&gt;www.sign.ac.uk/methodology/checklists.html&lt;/a&gt;). An objective appraisal of study quality is essential, but paired reviewing by guideline leads may be impractical because of resource constraints.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Once evidence has been collated and appraised, it can be graded. A judgement on the quality of the evidence will be necessary using the grading system (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field). Where evidence is felt to warrant 'down-grading', for whatever reason, the rationale must be stated. Evidence judged to be of poor quality can be excluded. Any study with a high chance of bias (either 1&amp;ndash; or 2&amp;ndash;) will be excluded from the guideline and recommendations will not be based on this evidence. This prevents recommendations being based on poor-quality RCTs when higher-quality observational evidence is available.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Informal Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Guideline Development&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The development of guidelines involves more than the collation and reviewing of evidence. Even with high-quality data from systematic reviews of randomised controlled trials, a value judgement is needed when comparing one therapy with another. This will therefore introduce the need for consensus.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Royal College of Obstetricians and Gynaecologists (RCOG) Green-top guidelines are drafted by nominated developers, in contrast to other guideline groups such as the National Institute for Health and Clinical Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN), who use larger guideline development groups. Equally, in contrast to other guideline groups, the topics chosen for development as Green-top guidelines are concise enough to allow development by a smaller group of individuals.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In agreeing the precise wording of evidence-based guideline recommendations and in developing consensus-based 'good practice points', the Guidelines Committee (GC) will employ an informal consensus approach through group discussion. In line with current methodologies, the entire development process will follow strict guidance and be both transparent and robust. The RCOG acknowledges that formal consensus methods have been described, but these require further evaluation in the context of clinical guideline development. It is envisaged that this will not detract from the rigor of the process but prevent undue delays in development.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Grades of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - At least one meta-analysis, systematic review or randomised controlled trial rated as 1++ and directly applicable to the target population; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A systematic review of randomised controlled trials or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - A body of evidence including studies rated as 2++ directly applicable to the target population, and demonstrating overall consistency of results; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Extrapolated evidence from studies rated as 1++ or 1+&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Extrapolated evidence from studies rated as 2++&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Evidence level 3 or 4; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Extrapolated evidence from studies rated as 2+&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good Practice Point&lt;/strong&gt; - Recommended best practice based on the clinical experience of the guideline development group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Following discussion in the Guidelines Committee (GC), each Green-top guideline is formally peer reviewed. At the same time, the draft guideline is published on the Royal College of Obstetricians and Gynaecologists (RCOG) Web site for further peer discussion before final publication.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All comments will be collated by the RCOG and tabulated for consideration by the guideline leads. Each comment will require discussion. Where comments are rejected then justification will need to be made. Following this review, the document will be updated and the GC will then review the revised draft and the table of comments.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Once the GC signs-off on the guideline, it is submitted to the Standards Board for approval before final publication.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;In addition to these evidence-based recommendations, the guideline development group also identifies points of best clinical practice in the original guideline document.&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Classification of evidence levels (&lt;strong&gt;1++ to 4&lt;/strong&gt;) and grades of recommendations (&lt;strong&gt;A-D&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Information Needs to Be Included in History Taking and Examination When Women Are Referred to the Gynaecology Clinic with Symptoms and/or Signs of a Vulval Skin Disorder to Aid Investigation and Management?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The history should include details of any personal or family history of autoimmune conditions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The history should include details of any personal or family history of atopic conditions (hay fever, asthma, eczema).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The history should include any symptoms of urinary or faecal incontinence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Which Investigations Are Useful in the Investigation of a Woman with a Vulval Skin Disorder?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - In the initial assessment of a woman with vulval symptoms, consider testing for thyroid disease, diabetes and sexually transmitted infections if clinically indicated.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Skin biopsy is not necessary when a diagnosis can be made on clinical examination. Biopsy is required if the woman fails to respond to treatment or there is clinical suspicion of vulvar intraepithelial neoplasia (VIN) or cancer.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Women suspected of having lichen sclerosus or lichen planus should be investigated for other autoimmune conditions if there are clinical symptoms or signs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Serum ferritin should be checked in women with vulval dermatitis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Is the Role of Skin Patch Testing in the Investigation and Management of Women with Vulval Dermatoses?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Skin patch testing should be performed for women seen with vulval dermatitis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;How Should Lichen Sclerosus and Lichen Planus Be Managed?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Ultrapotent steroids are important in the management of women diagnosed with lichen sclerosus and lichen planus. The patient and her general practitioner require clear advice on the management regime (Appendix 6 in the original guideline document describes a suitable management regime).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Approximately 4% to 10% of women with anogenital lichen sclerosus will have symptoms that do not improve with topical ultrapotent steroids (steroid-resistant disease). The recommended second-line treatment is topical tacrolimus under the supervision of a specialist clinic.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Surgery and CO&lt;sub&gt;2&lt;/sub&gt; laser vaporisation are not recommended for the treatment of symptoms of lichen sclerosus. However, these treatments have a role in restoring function impaired by agglutination and adhesions such as urinary retention or narrowing of the vaginal introitus that affect sexual function or body image.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;How Should VIN Be Managed?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The gold standard for the treatment of VIN is local surgical excision.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Women undergoing surgical excision of VIN should have access to reconstructive surgery.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Non-surgical treatments are accepted as an alternative to surgery, but women require regular, long-term follow-up.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Non-specific Measures and Advice Are Useful in the Control of Vulval Symptoms?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - A key part of management is general care of the vulval skin and avoidance of any potential irritants that may worsen vulval irritation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Emollients are widely recognised as having a key role in protecting the skin and restoring skin barrier function. General vulval care includes avoiding potential irritants that may worsen vulval symptoms. Uncontrolled studies have shown that these measures reduce symptoms and resolve contact dermatitis and lichen simplex chronicus. Vulval skin is sensitive and may react both to irritants and to allergens. Irritants are commonly encountered and include underwear, sanitary protection, textile dyes, soaps and detergents (see Appendix 3 in the original guideline document). Avoiding soap and detergents and using soap substitutes can be soothing and protective to the skin. The combined use of emollients and soap substitutes helps maintain symptom relief and is safe and inexpensive. A small, prospective, open trial of maintenance with an emollient following steroid therapy showed that a proportion of women can maintain symptom relief and reduce the use of topical corticosteroids. [&lt;strong&gt;Evidence level 3&lt;/strong&gt;]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Do Women with Vulval Skin Disorders Need to Remain Under Long-Term Surveillance at the Gynaecology Clinic?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Women with VIN need to be seen on a regular basis for vulvoscopy or careful clinical assessment and biopsy of any suspicious area.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Women who have been treated for VIN are at risk of intraepithelial neoplasia at other sites. Colposcopy examination should be available at follow-up.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;How Should Sexual Problems Associated with Vulval Skin Disorders Be Identified and, if Identified, What Is the Most Effective Approach to Their Management?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Women should be asked about the impact of their vulval disorder on sexual function and appropriate advice and care should be available.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Is the Role of Self-Examination and What Information Should Women Be Given on This?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Women with vulval symptoms should be encouraged to perform self-examination to monitor their skin condition and any suspicious areas.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Training Should General Gynaecologists Have in the Management of Vulval Disorders?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - According to the Royal College of Obstetricians and Gynaecologists (RCOG) core curriculum, obstetrics and gynaecology trainees must have knowledge and experience of the management of common vulval disorders as a training requirement.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Is the Most Effective Model for Care Provision for the Investigation and Management of Women with Vulval Skin Disorders?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Women with complex or rare vulval skin disorders or who do not respond to standard treatment should be seen at a specialist vulval clinic.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Women who have difficulty with symptom control should be referred to a specialist clinic. This includes women who require frequent or prolonged use of ultrapotent topical steroids. Such women may require additional support to use first-, second- or third-line therapy. They require biopsy of any suspicious or resistant areas.&lt;strong&gt; &lt;/strong&gt;[&lt;strong&gt;Evidence level 4&lt;/strong&gt;]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grades of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - At least one meta-analysis, systematic review or randomised controlled trial rated as 1++ and directly applicable to the target population; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A systematic review of randomised controlled trials or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - A body of evidence including studies rated as 2++ directly applicable to the target population, and demonstrating overall consistency of results; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Extrapolated evidence from studies rated as 1++ or 1+&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Extrapolated evidence from studies rated as 2++&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Evidence level 3 or 4; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Extrapolated evidence from studies rated as 2+&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good Practice Point&lt;/strong&gt; - Recommended best practice based on the clinical experience of the guideline development group&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Classification of Evidence Levels&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1++&lt;/strong&gt; High-quality meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a very low risk of bias&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1+&lt;/strong&gt; Well-conducted meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a low risk of bias&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1&amp;ndash;&lt;/strong&gt; Meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a high risk of bias&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2++&lt;/strong&gt; High-quality systematic reviews of case&amp;ndash;control or cohort studies or high-quality case&amp;ndash;control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2+&lt;/strong&gt; Well-conducted case&amp;ndash;control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2&amp;ndash;&lt;/strong&gt; Case&amp;ndash;control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;3&lt;/strong&gt; Non-analytical studies, e.g., case reports, case series&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;4&lt;/strong&gt; Expert opinion&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Improved accuracy of diagnosis and the implementation of adequate and appropriate treatment for vulval skin disorders&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Use of calcineurin inhibitors in anogenital lichen sclerosus is off-licence and should only be undertaken in a specialist clinic. The long-term safety of topical calcineurin inhibitors is not established; however, based on reports of extensive use, safety would appear to be low. While awaiting long-term data, use for longer than 2 years is not recommended owing to concerns about potential malignant transformation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of imiquimod cream include pain, erythema and swelling and can result in non-compliance. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Primary closure following excision of small lesions of vulvar intraepithelial neoplasia (VIN) can produce good results without tension, scarring or disruption to normal anatomy. However, with larger lesions, multifocal lesions or certain anatomical sites, scarring and tension can result in pain and psychosexual morbidity. It is important that women are offered reconstructive surgery. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;These recommendations are not intended to dictate an exclusive course of management or treatment. They must be evaluated with reference to individual patient needs, resources and limitations unique to the institution and variations in local populations. It is hoped that this process of local ownership will help to incorporate these guidelines into routine practice. Attention is drawn to areas of clinical uncertainty where further research may be indicated. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Royal College of Obstetricians and Gynaecologists (RCOG) produces guidelines as an educational aid to good clinical practice. They present recognised methods and techniques of clinical practice, based on published evidence, for consideration by obstetricians and gynaecologists and other relevant health professionals. The ultimate judgement regarding a particular clinical procedure or treatment plan must be made by the doctor or other attendant in the light of clinical data presented by the patient and the diagnostic and treatment options available. This means that RCOG guidelines are unlike protocols or guidelines issued by employers, as they are not intended to be prescriptive directions defining a single course of management. Departure from the local prescriptive protocols or guidelines should be fully documented in the patient's case notes at the time the relevant decision is taken. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Patient Resources" /><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Resources" /><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Royal College of Obstetricians and Gynaecologists (RCOG). The management of vulval skin disorders. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2011 Feb. 23 p.&amp;nbsp;(Green-top guideline; no. 58).&amp;nbsp; [83 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2011 Feb" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Royal College of Obstetricians and Gynaecologists - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Royal College of Obstetricians and Gynaecologists&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guidelines Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Authors&lt;/em&gt;: Dr ME Cruickshank FRCOG, Aberdeen, Scotland; Dr I Hay FRCP, Consultant Dermatologist, Royal Alexandra Hospital, Paisley, Scotland&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Peer Reviewers&lt;/em&gt;: British Society for the Study of Vulval Disease; RCOG Consumers' Forum; Faculty of Sexual and Reproductive Health; Lichen Sclerosus Support Group and the Vulval Health Awareness Campaign; Vulval Pain Society; Dr SE Barton FRCOG, London; Dr DL Bisson FRCOG, Bristol; Mrs A Diyaf MRCOG, Birmingham&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Guidelines Committee Lead Peer Reviewers&lt;/em&gt;: Dr A Thomson MRCOG, Glasgow, Scotland; Mrs C Overton FRCOG, Bristol; Dr NA Siddiqui FRCOG, Glasgow, Scotland&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Declaration of interests: None declared.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.rcog.org.uk/womens-health/clinical-guidance/management-vulval-skin-disorders-green-top-58&quot; title=&quot;RCOG Web site&quot;&gt;Royal College of Obstetricians and Gynaecologists (RCOG) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Development of RCOG Green-top guidelines: policies and processes. Clinical Governance Advice No 1a. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2006 Nov. 6 p. Electronic copies: Available from the &lt;a href=&quot;http://www.rcog.org.uk/green-top-development&quot; title=&quot;RCOG Web site&quot;&gt;Royal College of Obstetricians and Gynaecologists (RCOG) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Development of RCOG Green-top guidelines: producing a scope. Clinical Governance Advice No 1b. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2006 Nov. 4 p. Electronic copies: Available from the &lt;a href=&quot;http://www.rcog.org.uk/womens-health/clinical-guidance/development-rcog-green-top-guidelines-producing-scope&quot; title=&quot;RCOG Web site&quot;&gt;RCOG Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Development of RCOG Green-top guidelines: producing a clinical practice guideline. Clinical Governance Advice No 1c. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2006 Nov. 13 p. Electronic copies: Available from the &lt;a href=&quot;http://www.rcog.org.uk/womens-health/clinical-guidance/development-rcog-green-top-guidelines-producing-clinical-practice-gu&quot; title=&quot;RCOG Web site&quot;&gt;RCOG Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Development of RCOG Green-top guidelines: consensus methods for adaptation of Green-top guidelines. Clinical Governance Advice No 1d. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2010 Feb. 9 p. Electronic copies: Available from the &lt;a href=&quot;http://www.rcog.org.uk/development-of-rcog-green-top-guidelines-consensus-methods&quot; title=&quot;RCOG Web site&quot;&gt;RCOG Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The following is also available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Vulval disease. Advanced training skills module. Royal College of Obstetricians and Gynaecologists (RCOG); 2010 Aug. 6 p. Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.rcog.org.uk/files/rcog-corp/ED-ATSM-Vulval-Disease.pdf&quot; title=&quot;RCOG Web site&quot;&gt;RCOG Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;In addition, recommendations for audit are available in section 15 of the &lt;a href=&quot;http://www.rcog.org.uk/files/rcog-corp/GTG58Vulval22022011.pdf&quot; title=&quot;RCOG Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The appendices of the &lt;a href=&quot;http://www.rcog.org.uk/files/rcog-corp/GTG58Vulval22022011.pdf&quot; title=&quot;RCOG Web site&quot;&gt;original guideline document&lt;/a&gt; contain various resources, including an executive summary, a description of common vulval skin disorders, and an example of a patient questionnaire.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patient information on general care of vulval skin is available in Appendix 3 and information on the use of clobetasol propionate 0.05% cream or ointment is available in Appendix 6 of the &lt;a href=&quot;http://www.rcog.org.uk/files/rcog-corp/GTG58Vulval22022011.pdf&quot; title=&quot;RCOG Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on January 26, 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
